October Drug Recalls
This article was originally published in The Gold Sheet
You may also be interested in...
Recall Roundup: tainted heparin, glass flakes, odorous bottles and more
Economically motivated adulteration, glass flakes in vials, out-of-specification transdermal patches, malodorous bottles and prefilled syringe sterility were among the more significant manufacturing quality issues leading to drug recalls in the past three months.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.